Engineered Skin Substitute ESS was estimated to b

Engineered Skin Substitute
ESS was estimated to be worth 1.8B and that was BEFORE DoD backing, ODD, IND, Phase 2 trial starting.

http://investorshangout.com/post/view?id=3045103

http://investorshangout.com/post/view?id=3046498



MANF Ophthalmology
AGTC is in the early Ophthalmology stage similar to Amarantus...

Quote:

---

Under the terms of the agreements, Biogen will make near-term payments including an upfront payment in the amount of $124 million to AGTC, which includes a $30 million equity investment at a purchase price of $20.63 per share. AGTC is eligible to receive upfront and milestone payments exceeding $1 billion in total. Biogen will be granted a license to the XLRS and XLRP programs and the option to license discovery programs for three additional indications at the time of clinical candidate selection.

---

MSPrecise and LymPro

Quote:

---

Taken together, MSPrecise and LymPro may not be your traditional therapeutic drug blockbusters, but the amount of money they are designed to save both insurance companies and patients in terms of false positives far exceeds the $1B annual blockbuster threshold. With CLIA approval expected this year for both and sales beginning this quarter for LymPro and next year for MSPrecise, the prospect of a significant revaluation for Amarantus from today’s $60M seems relatively decent.

---

http://biotechstocks.com/inside-amarantuss-10...spotlight/


Eltoprazine
Adamas got Orphan approval for LID. They have one drug in phase 3 and another in phase 2. Market cap is $350M . Eltoprazine also has additional potential in ADHD and Alzheimer Aggression.

http://finance.yahoo.com/news/agtc-announces-...00623.html